Abstracts tagged "physical function"

Abstract Number: 0931 • ACR Convergence 2020
Oropharyngeal Dysfunction in Patients with Systemic Sclerosis – Results of a Monocentric Clinical Study
Philipp Klemm¹, Mirjam Wirths², Ole Hudowenz², Ulrike Hoffmann³, Ulf Müller-Ladner² and Uwe Lange², ¹Department of Rheumatology, Immunology, Osteology and Physical Medicine, Justus Liebig University Gießen, Campus Kerckhoff, Bad Nauheim, Germany, Bad Nauheim, Hessen, Germany, ²Department of Rheumatology, Immunology, Osteology and Physical Medicine, Justus Liebig University Gießen, Campus Kerckhoff, Bad Nauheim, Germany, Bad Nauheim, Germany, ³Practice for Speech Therapy Ulrike Hoffmann, Friedberg, Germany
Background/Purpose: Nearly 98% of patients with systemic sclerosis (SSc) are suffering from gastrointestinal involvement (Schmeiser et al. 2012). While in everyday clinical practice screening for…
Abstract Number: 1084 • ACR Convergence 2020
Consumer-based Activity Trackers in Evaluation of Physical Function in Myositis Patients
Didem Saygin¹, Bonny Rockette-Wagner², Chester Oddis³, Diane Koontz¹, Siamak Moghadam-Kia¹ and Rohit Aggarwal², ¹University of Pittsburgh Medical Center, Pittsburgh, PA, ²University of Pittsburgh, Pittsburgh, PA, ³Department of Medicine, Division of Rheumatology, University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Idiopathic inflammatory myopathies are systemic inflammatory conditions characterized by muscle weakness and reduced muscle endurance that limit activities of daily living. Daily step count…
Abstract Number: 1110 • ACR Convergence 2020
Osteoarthritis-Related Knee Inflammation Measured by Ultrasound Is Associated with Performance-Based Measures of Function
Holly Philpott¹, Trevor Birmingham², Ryan Pinto², Dominique Arsenault², Codie Primeau², Edward Vasarhelyi³, Steven MacDonald³, Brent Lanting³ and Tom Appleton⁴, ¹Western University, London, ON, Canada, ²Western University, London, Canada, ³London Health Sciences Centre, London, Canada, ⁴The University of Western Ontario, LONDON, ON, Canada
Background/Purpose: Signs of inflammation in knee osteoarthritis (OA), including synovitis, are associated with worse clinical outcomes such as increased pain, risk of progression, and future…
Abstract Number: 1341 • ACR Convergence 2020
Improvement in Patient-Reported Outcomes in Patients with Psoriatic Arthritis with Inadequate Response to Non-Biologic DMARDs Treated with Upadacitinib versus Placebo or Adalimumab: Results from a Phase 3 Study
Vibeke Strand¹, Philip Mease², Enrique Soriano³, Mitsumasa Kishimoto⁴, Carlo Salvarani⁵, Nemanja Damjanov⁶, Jaclyn K Anderson⁷, Erin Blondell⁷, Patrick Zueger⁷, Christopher Saffore⁷ and Dafna Gladman⁸, ¹Division of Immunology/Rheumatology, Stanford University, Palo Alto, CA, ²Seattle Rheumatology Associates, P.L.L.C., Seattle, WA, ³Department of Public Health, Instituto Universitario, Escuela de Medicina Hospital Italiano de Buenos Aires, Buenos Aires, Argentina; Rheumatology Unit, Internal Medicine Services, Hospital Italiano de Buenos Aires, Capital Federal, Buenos Aires, Argentina, ⁴Department of Nephrology and Rheumatology, Kyorin University School of Medicine, Yokohama, Japan, ⁵Rheumatology Units, University of Modena and Reggio Emilia, and Azienda USL-IRCCS di Reggio Emilia, REGGIO EMILIA, Italy, ⁶University of Belgrade Medical School, Belgrade, Serbia, ⁷AbbVie Inc., North Chicago, IL, ⁸Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: Patient-reported outcomes (PROs) are important when evaluating treatment benefits in PsA. We present an analysis of PRO data from the SELECT-PsA 1 study.Methods: SELECT-PsA…
Abstract Number: 1371 • ACR Convergence 2020
Improvement in Patient-Reported Outcomes for Upadacitinib versus Placebo Among Patients with Psoriatic Arthritis and an Inadequate Response to Biologic Disease-Modifying Anti-Rheumatic Drugs
Vibeke Strand¹, Filip Van den Bosch², Roberto Ranza³, Ying Ying Leung⁴, Edit Drescher⁵, Apinya Lertratanakul⁶, Ralph Lippe⁷, Christopher Saffore⁶, Patrick Zueger⁶ and Peter Nash⁸, ¹Division of Immunology/Rheumatology, Stanford University, Palo Alto, CA, ²Ghent University Hospital, Ghent, Belgium, ³Hospital de Clinicas, Universidade Federal de Uberlândia, Uberlândia, Brazil, ⁴Department of Rheumatology & Immunology, Singapore General Hospital, Singapore, Singapore, ⁵Veszprém Csolnoky Ferenc County Hospital, Veszprém, Hungary, ⁶AbbVie Inc., North Chicago, IL, ⁷AbbVie Deutschland GmbH & Co. KG, Wiesbaden, Germany, ⁸School of Medicine Griffith University, Brisbane, Queensland, Australia
Background/Purpose: The efficacy and safety of upadacitinib (UPA), a selective Janus kinase inhibitor, in patients with PsA is under investigation in Phase 3 clinical trials.…
Abstract Number: 1459 • ACR Convergence 2020
The Association of Frequent Knee Bending with Trajectories of Pain and Physical Function over 8 Years in Knee Osteoarthritis
Jason Jakiela¹, Dana Voinier¹, Thomas Bye¹, Maria Tukis¹, Kiely Konyak¹, Dylan Orloff¹ and Daniel White¹, ¹University of Delaware, Newark, DE
Background/Purpose: Frequent bending increases loading at the knee and is a risk factor for worsening knee pain associated with knee osteoarthritis (OA). Knee bending is…
Abstract Number: 1641 • ACR Convergence 2020
Clinically Important Improvements in Patients with Osteoarthritis Treated with Subcutaneous Tanezumab: Results from a 56-Week Randomized NSAID-Controlled Study
David Hunter¹, Tuhina Neogi², Melvin Churchill³, Ivan Shirinsky⁴, Masanari Omata⁵, Alexander White⁶, Ali Guermazi², Robert Fountaine⁷, Glenn Pixton⁸, Lars Viktrup⁹, Mark Brown⁷, Christine West¹⁰ and Kenneth Verburg¹¹, ¹Institute of Bone and Joint Research, University of Sydney, St Leonards, New South Wales, Australia, ²Boston University School of Medicine, Boston, MA, ³Arthritis Center of Nebraska, Lincoln, NE, ⁴Federal State Budgetary Scientific Institution Research Institute of Fundamental and Clinical Immunology, Novosibirsk, Russia, ⁵Ohimachi Orthopaedic Clinic, Tokyo, Japan, ⁶Progessive Medical Research, Port Orange, FL, ⁷Pfizer Inc., Groton, CT, ⁸Pfizer Inc., Morrisville, NC, ⁹Eli Lilly and Company, Indianapolis, IN, ¹⁰Pfizer Inc, Groton, CT, ¹¹Pfizer Inc, Groton
Background/Purpose: Subcutaneous (SC) tanezumab, a monoclonal antibody that inhibits nerve growth factor, was investigated for the relief of signs and symptoms of moderate-severe OA in…
Abstract Number: 1642 • ACR Convergence 2020
Observed Efficacy with Subcutaneous Tanezumab Is Early and Maintained in Patients with Osteoarthritis: Results from a 56-Week Randomized NSAID-Controlled Study
Tuhina Neogi¹, David Hunter², Melvin Churchill³, Ivan Shirinsky⁴, Masanari Omata⁵, Alexander White⁶, Ali Guermazi¹, Robert Fountaine⁷, Glenn Pixton⁸, Lars Viktrup⁹, Mark Brown⁷, Christine West¹⁰ and Kenneth Verburg¹¹, ¹Boston University School of Medicine, Boston, MA, ²Institute of Bone and Joint Research, University of Sydney, St Leonards, New South Wales, Australia, ³Arthritis Center of Nebraska, Lincoln, NE, ⁴Federal State Budgetary Scientific Institution Research Institute of Fundamental and Clinical Immunology, Novosibirsk, Russia, ⁵Ohimachi Orthopaedic Clinic, Tokyo, Japan, ⁶Progessive Medical Research, Port Orange, FL, ⁷Pfizer Inc., Groton, CT, ⁸Pfizer Inc., Morrisville, NC, ⁹Eli Lilly and Company, Indianapolis, IN, ¹⁰Pfizer Inc, Groton, CT, ¹¹Pfizer Inc, Groton
Background/Purpose: Subcutaneous (SC) tanezumab, a monoclonal antibody that inhibits nerve growth factor, was investigated for the relief of signs and symptoms of moderate-severe OA in…
Abstract Number: 1645 • ACR Convergence 2020
Placebo Group Responses in Clinical Trials of Patients with Osteoarthritis: Data from the Tanezumab Development Program
Luana Colloca¹, Robert Dworkin², John Farrar³, Leslie Tive⁴, Ed Whalen⁵, Jerry Yang⁴, Lars Viktrup⁶, Mark Brown⁷, Christine West⁷ and Kenneth Verburg⁸, ¹University of Maryland, Baltimore, ²University of Rochester School of Medicine and Dentistry, Rochester, NY, ³University of Pennsylvania, Philadelphia, PA, ⁴Pfizer Inc, New York, NY, ⁵Pfizer Inc, New York, ⁶Eli Lilly and Company, Indianapolis, IN, ⁷Pfizer Inc, Groton, CT, ⁸Pfizer Inc, Groton
Background/Purpose: The level of placebo group response in clinical trials for chronic pain conditions is a concern for the development of novel analgesics1. Here, we…
Abstract Number: 1647 • ACR Convergence 2020
An Oleuropein-based Dietary Supplement Improves Joint Function in Older People with High Knee Joint Pain
Marie-Noelle Horcajada¹, Maurice Beaumont², Nicolas Sauvageot², Madleen Saboundjian¹, Laure Poquet¹, Anne-Christine Hick³, Berenice Costes⁴ and Yves Henrotin⁵, ¹Nestle Research, EPFL Innovation Park, Lausanne, Switzerland, ²Nestle Research, Clinical Development Unit, Lausanne, Switzerland, ³Artialis SA, Liège, Belgium, ⁴Artialis SA, Liege, Belgium, ⁵University of Liège, Liège, Belgium
Background/Purpose: The aim of this study was to investigate the effects of a 6-month intervention with an Olive Leaf Extract (OLE) standardized for oleuropein content…
Abstract Number: 561 • 2019 ACR/ARP Annual Meeting
Analysing Impairments in Physical Performance as Assessed by the as Performance Index (ASPI) in Patients with Axial Spondyloarthritis (axSpA)
Eerik Ahomaa ¹, Uta Kiltz², Björn Bühring ³, Xenofon Baraliakos ⁴, Salima van weely ⁵ and Jürgen Braun ⁶, ¹Rheumazentrum Ruhrgebiet and Ruhr-University Bochum, Bochum, Germany, ²Rheumazentrum Ruhrgebiet/Ruhr University Bochum, Herne, Germany, Herne, Germany, ³Rheumazentrum Ruhrgebiet and Ruhr-University Bochum, Herne, Germany, ⁴Rheumazentrum Ruhrgebiet-Ruhr-University Bochum, Herne, Germany, Herne, Germany, ⁵Orthopedics, Rehabilitation and Physical Therapy dpt., Leiden University Medical Center, Leiden, Netherlands, ⁶Rheumazentrum Ruhrgebiet/Ruhr University, Herne, Germany
Background/Purpose: In patients with axial spondyloarthritis (axSpA) physical functioning is frequently impaired. The current gold standard to assess physical functioning is self-reported questionnaires (i.e. BASFI),…
Abstract Number: 612 • 2019 ACR/ARP Annual Meeting
Objective Ankylosing Spondylitis Physical Performance Index (ASPI) Is Highly Reliable and Feasible in Chilean Patients
Rianne van Bentum¹, Sebastian Ibáñez Vodnizza ², Francisca Valenzuela Aldridge ², Maria Paz Poblete ³, Salima van weely ⁴, Marieke ter Wee ¹, Omar Valenzuela ⁵ and Irene van der Horst-Bruinsma ¹, ¹Amsterdam Rheumatology and immunology Center, Rheumatology, Amsterdam University Medical Center location VUmc, Amsterdam, Amsterdam, Netherlands, ²Rheumatology dpt., Clínica Alemana - UDD Medicine faculty, Santiago, Chile, ³Rheumatology dpt., Facultad de Medicina Clinica Alemana - UDD, Santiago, Region Metropolitana, Chile, ⁴Orthopedics, Rehabilitation and Physical Therapy dpt., Leiden University Medical Center, Leiden, Netherlands, ⁵Facultad de Medicina Clinica Alemana -UDD, Santiago, Region Metropolitana, Chile
Background/Purpose: In axial spondyloarthritis (axSpA), preservation of physical functioning is an important treatment goal and is usually assessed with the patient-reported BASFI questionnaire. The Ankylosing…
Abstract Number: 1170 • 2019 ACR/ARP Annual Meeting
Cortical Bone Erosion in the 2nd Metacarpal Bone Head: Association with Its Bone Mineral Density by HR-pQCT in Rheumatoid Arthritis Patients
Camille Figueiredo¹, Mariana Perez ¹, Ana Cristina de Medeiros Ribeiro ², Valeria Caparbo ¹ and Rosa Pereira ³, ¹Faculdade de Medicina da Universidade de Sao Paulo, Sao Paulo, Sao Paulo, Brazil, ²Hospital das Clinicas da Faculdade de Medicina da Universidade de Sao Paulo, Sao Paulo, Sao Paulo, Brazil, ³Faculdade de Medicina da Universidade de Sao Paulo, São Paulo, Sao Paulo, Brazil
Background/Purpose: Periarticular trabecular bone loss and local cortical bone erosions are typical features of bone disease in rheumatoid arthritis (RA) 1 . Little, however, is…
Abstract Number: 1314 • 2019 ACR/ARP Annual Meeting
Patient-Specific Reference Values for Objective Physical Function Tests: Cross-Sectional Analysis Using Data from the Osteoarthritis Initiative
Matthew Harkey¹, Lori Lyn Price ², Kieran Reid ³, Grace Lo ⁴, Shao-Hsien Liu ⁵, Kate Lapane ¹, Lucas Dantas ⁶, Timothy McAlindon ⁷ and Jeffrey Driban ⁷, ¹University of Massachusetts Medical School, Worcester, ²Tufts Medical Center, Tufts University, Boston, MA, ³Tufts University, Boston, ⁴Center of Excellence Michael E. DeBakey VAMC, Baylor College of Medicine, Houston, TX, ⁵University of Massachusetts Medical School, Worcester, MA, ⁶Tufts Medical Center, Boston, ⁷Tufts Medical Center, Boston, MA
Background/Purpose: Despite an inter-play between objective physical function measures and various patient characteristics, no large-scale investigations in knee osteoarthritis (KOA) have explored complex interactions or…
Abstract Number: 1352 • 2019 ACR/ARP Annual Meeting
Effects of Upadacitinib on Patient-Reported Outcomes After 24 Weeks in Patients with Active Rheumatoid Arthritis and an Inadequate Response to Conventional Synthetic or Biologic Disease-Modifying Anti-Rheumatic Drugs: Results from SELECT-NEXT and SELECT-BEYOND Phase 3 Studies
Martin Bergman¹, Namita Tundia ², Heidi Camp ², Sebastian Meerwein ³, Casey Schlacher ², Debbie Goldschmidt ⁴, Yan Song ⁵ and Vibeke Strand ⁶, ¹Drexel University College of Medicine, Stockholm, Sweden, ²AbbVie Inc., North Chicago, IL, ³AbbVie GmbH Co. KG, Ludwigshafen, Germany, Wiesbaden, Germany, ⁴Analysis Group, Inc., New York, NY, ⁵Analysis Group, Inc., Boston, MA, ⁶Division of Immunology/Rheumatology, Stanford University, Stanford, CA
Background/Purpose: Treatment with upadacitinib (UPA), a selective Janus kinase-1 (JAK-1) inhibitor, resulted in significant and clinically meaningful improvements in patient-reported outcomes (PROs) at Week 12…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].